24.720USD+24.720盤後交易 (美東)
關鍵數據
24.985今開
25.235最高
81.99M成交量
18.77本益比TTM
8.75本益比動
1.720股利TTM
1.44%換手率
25.080昨收
24.690最低
1.19B成交額
17.50本益比靜
1.63市淨率
6.96%股息率 TTM
3.62%ROA
28.74552週最高
1.58量比
8.03B淨利潤
5.69B總股本
1.3167每股盈餘TTM
0.30Beta
8.29%ROE
23.06052週最低
2.17%振幅
68.24%毛利率
140.56B總市值
-2.36回報/風險
1.34%風險率
操作建議
輝瑞當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名78/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為29.06。中期看,股價處於平穩狀態。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
輝瑞簡介
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
公司代碼PFE
公司輝瑞
CEOBourla (Albert)
網址https://www.pfizer.com/
常見問題
根據分析師評級,輝瑞(PFE)的總體評級為signal_hold,目標價格為29.06。
輝瑞(PFE)股票的每股收益(EPS TTM)是多少
輝瑞(PFE)股票的每股收益(EPS TTM)是1.37。